Current Report Filing (8-k)
November 08 2018 - 5:42AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported):
November 8, 2018
BioTime,
Inc.
(Exact name of registrant as specified in its charter)
California
|
|
1-12830
|
|
94-3127919
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
1010
Atlantic Avenue
Suite
102
Alameda,
California 94501
(Address
of principal executive offices)
(510)
521-3390
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☒
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
c
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
c
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
c
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
c
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
c
Forward-Looking
Statements
Any
statements that are not historical fact (including, but not limited to statements that contain words such as “may,”
“will,” “believes,” “plans,” “intends,” “anticipates,” “expects,”
“estimates”) should also be considered to be forward-looking statements. Additional factors that could cause actual
results to differ materially from the results anticipated in these forward-looking statements are contained in BioTime’s
periodic reports filed with the SEC under the heading “Risk Factors” and other filings that BioTime may make with
the Securities and Exchange Commission. Undue reliance should not be placed on these forward-looking statements which speak only
as of the date they are made, and the facts and assumptions underlying these statements may change. Except as required by law,
BioTime disclaims any intent or obligation to update these forward-looking statements.
References
in this Report to “BioTime,” “we” or “us” refer to BioTime, Inc.
This
Report and the accompanying Exhibit 99.1 shall be deemed “furnished” and not “filed” under Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of
that section, and shall not be incorporated by reference into any filings made by BioTime under the Securities Act of 1933, as
amended, or the Exchange Act except as may be expressly set forth by specific reference in such filing.
Item
2.02 - Results of Operations and Financial Condition
On
November 8, 2018, BioTime, Inc. issued a press release announcing its financial results for the three and nine months ended September
30, 2018. A copy of the press release is attached as Exhibit 99.1, which, in its entirety, is incorporated herein by reference.
Item
9.01 - Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
BIOTIME, INC.
|
|
|
|
Date:
November 8, 2018
|
By:
|
/s/
Brian Culley
|
|
|
Chief
Executive Officer
|
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2024 to May 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From May 2023 to May 2024